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Shedding
Light on
a Hidden
Disease
By Katherine Unger Baillie

D

oberman pinschers are stately, strong and
intelligent, seemingly unflappable. Yet members
of this breed are more likely than any other to
succumb to an insidious, inherited condition
that can silently kill.
Dilated cardiomyopathy (DCM) is the
second most common acquired heart disease seen in dogs,
behind mitral valve disease. It’s particularly prevalent in
Dobermans.
“As many as 40 percent of Doberman pinschers are going
to get dilated cardiomyopathy at some point in their life,” said
Mark Oyama, DVM, a professor of cardiology at Penn Vet. “So
clearly it’s a big problem for the breed.”
DCM, which is typically an inherited condition in
canines, also commonly strikes other large breeds such as Irish
Wolfhounds and Great Danes. Fortunately for these dogs
and their owners, Dr. Oyama is one of a growing number of
researchers with a goal of finding better ways to screen and treat
pets that have or are likely to develop DCM.
Among the challenges of this pursuit is the disease’s hidden
nature.
“Oftentimes a dog will be developing or have dilated
cardiomyopathy and yet show no outward signs of it,” said
Dr. Oyama. “So you have owners who think their dog is
completely normal and yet they’re walking around with heart
disease.”
Sometimes, the first overt sign that a dog has DCM is
it suddenly collapses and dies. But many dogs do display
symptoms, which may include labored breathing, coughing,
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fainting, exercise intolerance, restlessness and lethargy. All of
these result from the central feature of DCM, which is the
weakening of the heart muscle.
While researchers don’t fully understand the mechanism of
disease, they do know it has to do with a malfunction in the
way that heart muscle cells operate at their fundamental or
cellular level. As a result of these disruptions on the molecular
and cellular levels, the chambers of the heart dilate and their
walls thin. The heart’s pumping action weakens and fails to
adequately circulate blood through the body. This, in turn, leads
to congestive heart failure.
Sudden cardiac death can occur without any previous
symptoms because a heart damaged by DCM may beat in an
abnormal rhythm and arrest. The disease can be devastating for
dog owners who would have otherwise expected to have several
more years with their pet; DCM can strike Dobermans as young
as two years old and most dogs die within a year of diagnosis.

Toward Early Diagnosis
Currently, the gold standard for DCM diagnosis is to perform
a cardiac ultrasound (echocardiogram) and to monitor the heart
rhythm for 24 hours with an ambulatory electrocardiogram,
known as a Holter monitor. These screenings are not
inexpensive and while the expense may be justifiable for
the owner of a single Doberman, it could be prohibitive for
breeders who may wish to screen many dogs at once.

An X-ray of a dog’s heart with DCM.

The stakes are high for early diagnosis, because veterinarians
can intervene with drugs such as pimobendan, beta-blockers,
diuretics and ACE inhibitors that can slow the disease’s
progression. Thus, much of Dr. Oyama’s research on DCM has
focused on developing more accurate and less expensive ways
to diagnose the disease.
“One of the things that we looked at most recently is trying
to find out if you could do a blood test that would help you
decide if your dog has a high likelihood or a low likelihood
of having cardiomyopathy,” said Dr. Oyama. “That would
provide a kind of middle ground between doing nothing and
doing a full-blown diagnostic workup.”
In a publication just out in the Journal of Veterinary Internal
Medicine, Dr. Oyama and former Penn Vet resident Gretchen
Singletary, now a veterinary specialist at Cornell University
Veterinary Specialists, along with colleagues, describe a blood
test that can help discern whether a dog is in the early stages
of DCM. Examining 155 asymptomatic dogs, the researchers
measured blood concentrations of N-terminal pro-brain
natriuretic peptide, or NT-proBNP. The heart releases this
peptide when it is under stress, and other researchers have used
it as a marker of cardiac dysfunction in humans.
In the study, the researchers found that dogs with high
levels of NT-proBNP were more likely to have DCM and had
much shorter survival times than those with lower levels. This
assay alone, however, did not always reliably predict a dog’s
likelihood of being diagnosed with DCM without an ECG. A
solution to the lack of sensitivity was to pair the blood test with
continued on page 7
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Treating Heart Disease with Genes

W

hile Dr. Mark Oyama seeks better ways to
determine whether or not a dog has dilated
cardiomyopathy (DCM), Meg Sleeper, VMD is
refining approaches to treating DCM and other
heart conditions that may restore near-normal function to the
heart muscle. What she finds may reach beyond the veterinary
profession to improve human lives as well.
For nearly a decade, Dr. Sleeper, associate professor of
cardiology, has worked with colleagues at Penn and elsewhere to
develop gene therapy techniques to treat cardiac disease in dogs
and cats. Gene therapy aims to correct disease-causing genetic
abnormalities by using a non-pathogenic virus to “infect”
specific cells in a patient with a healthy version of a gene.
One beauty of the approach is that researchers needn’t
understand the exact molecular pathway that goes awry — and
for DCM, scientists don’t yet have this detailed knowledge.
Instead, they can zoom to the end of the pathway, correcting
the ultimate problem. For DCM, that means targeting the
protein pump that shuttles calcium in and out of cells. Using
gene therapy that helps boost levels of calcium inside the
cell, researchers can ensure the heart muscle maintains strong
contractions, staving off congestive heart failure.

Cardiac ultrasound of
a dog with DCM.

“With gene therapy what we’re doing is trying to get the
heart muscle to produce a protein of interest,” said Dr. Sleeper.
“So instead of having to give a drug every day, the muscle
cells just produce the molecule, in essence becoming the drug
manufacturer for us.”
Two different genes have functioned as these genetic “drugs”
in Dr. Sleeper’s early trials. One, called S100A1, enhances
calcium movement into heart muscle cells. The other blocks the
activity of the gene phospholamban, which normally reduces
movement of calcium into cells. The initial tests, conducted in
about 60 dogs, look promising.
“With the studies we’ve done so far we can get about 60 to 70
percent of the heart cells to express the genes we’re introducing,”
she said. “I’m hopeful that that is enough for a dog with DCM
to experience a big difference in their heart function.”
This initial phase of testing has also shown that the treatment
is safe in a variety of canine breeds, most of which did not have
DCM. Dr. Sleeper now has grant applications submitted with the
hope of experimentally treating Dobermans that do have DCM.
Not only might success in these trials bode well for dogs with
DCM, but also in humans with DCM and other heart conditions.
“If it turns out that we get really great results with either
phospholamban or S100A1 or both, then I think that gives
researchers really useful information for treating humans,” Dr.
Sleeper notes.
In people, DCM can be inherited but can also develop after a
heart attack or coronary disease. DCM can also be one symptom
of Duchenne muscular dystrophy, which affects one out of every
3,500 boys and is caused by a mutation in the dystrophin gene.
Together with Lee Sweeney, PhD, the William Maul Measey
Professor and chairman of physiology at Penn Medicine, and
others, Dr. Sleeper has used gene therapy to correct the problem
in the muscle tissue of dogs with the disease — an important
animal model for humans with muscular dystrophy.
Breakthroughs that rely on gene therapy are steadily increasing
in number. Another one of Dr. Sleeper’s collaborators, Penn
Vet’s Mark Haskins, VMD, PhD, has had excellent results
replacing a malfunctioning enzyme in dogs with a devastating
lysosomal storage disease. That treatment may soon enter clinical
trials in children with the fatal condition.
Such promising results with gene therapy put Dr. Sleeper and
other Penn Vet faculty at the cutting edge of medicine. “These
kinds of approaches,” she said, “give us a whole different way of
looking at disease.”
—By Katherine Unger Baillie
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continued from page 5

the Holter monitor — a combination that resulted in a very
specific and sensitive way to pre-screen dogs for disease. This
two-faceted approach may offer owners a less pricey alternative
to having vets perform an echocardiogram in addition to the
Holter monitor to see if their dog requires further examination.

Genes for Risk
Another strategy for early diagnosis of DCM is to screen dogs
for genes that predispose them to the condition.
“It seems realistic to think that there are breed-specific genetic
abnormalities that predispose Doberman pinschers to get dilated
cardiomyopathy,” said Dr. Oyama, “because the condition is so
prevalent within the breed.”
But even though there are hundreds of genes that have been
linked in humans with DCM, veterinary researchers have just
begun to discover parallel genes in dogs.
The search for these mutations is made difficult because large
populations are generally required to do genome-wide searches
for abnormal genes. A breakthrough on the genetic front came
earlier this year. Dr. Oyama was part of a team that reported on
their discovery in a study led by Dr. Kathryn Meurs of North
Carolina State University’s College of Veterinary Medicine.
Writing in the journal Human Genetics, Dr. Meurs’ team
screened 48 healthy Dobermans and 48 Dobermans with
diagnosed DCM for gene mutations that appeared prevalent in
the sick dogs. In their analysis, they found one mutation that
stood out in the DCM dogs. This abnormality, affecting the
gene PDK4, appears to alter the metabolism of the heart, shifting
it from burning fat — the heart’s preferred fuel — to sugar.

“Ultimately, this change could result in an energy-starved
state,” the authors write, leading to a weakening of the heart’s
contraction.
It’s clear that this one mutation is not responsible for all cases
of inherited DCM in Dobermans — 18 percent of the animals
with the disease in the study did not have the mutation. This
fact complicates the hope for a quick genetic screening test
for mutations that predisposes a dog to the disease. Such a test
would be especially valuable for breeders, who would be able to
use the procedure to identify individual animals to keep out of
their breeding pool.

A Brighter Future
Despite the cruel rapidity of DCM, a dog diagnosed with the
disease today is better off than it would have been 10 years ago.
Researchers including Dr. Oyama continue to seek therapies that
will dramatically decelerate the disease’s progression. Meanwhile,
other scientists, including Margaret M. Sleeper, VMD, associate
professor at Penn Vet, are aiming for treatments using gene
therapy (see sidebar).
“A long time ago there simply weren’t enough people who
were interested in studying cardiac diseases in dogs,” said Dr.
Oyama. “Now you have a critical mass of investigators, many
of whom collaborate and can look at multiple aspects of the
disease.”
Together, these veterinarian-scientists may soon render DCM
an eminently treatable — and one day, curable — condition.
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